A new factor Xa inhibitor for acute coronary syndrome
نویسندگان
چکیده
منابع مشابه
Role of oral factor Xa inhibitors after acute coronary syndrome.
Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic...
متن کاملA New Oral Direct Factor Xa Inhibitor
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in th...
متن کاملDirect Xa inhibitors in acute coronary syndrome.
cute coronary syndrome (ACS) is the major cause of morbidity and mortality in the world. Recent developments in ACS treatment have significantly improved the prognosis of ACS patients, but the risk of recurrent ischemic events remains still high.1 Even with dual antiplatelet therapy (DAPT), death, myocardial infarction (MI), or stroke occurs in 9–11% at 1 year after the ACS event.2 One potentia...
متن کاملEdoxaban: a new oral direct factor xa inhibitor.
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in th...
متن کاملEdoxaban (Savaysa): A Factor Xa Inhibitor.
INTRODUCTION Atrial fi brillation (AF), the most common cardiac arrhythmia, is encountered in clinical practice with ever-increasing frequency.1 Older data suggest that the lifetime risk of AF in men and women older than 40 years of age is approximately one in four.2 The prevalence of AF has most likely increased due to the aging of the “baby-boomers” (AF is overwhelmingly a disease of age) and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Cardiology
سال: 2009
ISSN: 1759-5002,1759-5010
DOI: 10.1038/nrcardio.2009.176